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Introduction: Anaplastic lymphoma kinase (ALK) rearrangements 
are present in an important subset of non–small-cell lung cancer 
(NSCLC) and predict for response to the tyrosine kinase inhibitor 
crizotinib. In this study, we evaluated the yet unknown frequency and 
functional role of ALK splicing isoforms in NSCLC.
Methods: We analyzed 270 cases of NSCLC for ALK kinase 
domain splicing aberrations and in addition generated constructs 
with  full-length echinoderm microtubule-associated protein-like 4 
(EML4)-ALK (E13;A20) and a splicing isoform.
Results: Splicing isoforms of the kinase domain of ALK—including 
complete skipping of exon 23 (ALKdel23, ALK p.I1171fs*42) and 
exon 27 (ALKdel27, ALK p.T1312fs*0)—were identified in 11.1% 
(30 of 270 cases) of NSCLC, and these changes coexisted with ALK 
rearrangements, KRAS mutations, and EGFR mutations. ALK splicing 
isoforms were observed with full-length EML4-ALK in  crizotinib-naive 
and treated NSCLCs. ALK T1312fs*0 was unable to render cells solely 
dependent on ALK signaling. Unlike EML4-ALK and  EML4-ALK 
p.L1196M, EML4-ALK T1312fs*0 did not autophosphorylate ALK 
or other phosphotyrosine sites. Coexpression of equal amounts of 
 EML4-ALK T1312fs*0 and EML4-ALK did not result in resistance 
to crizotinib, whereas coexpression of EML4-ALK L1196M with 
 EML4-ALK resulted in resistance to inhibition of ALK by crizotinib.
Conclusions: ALK kinase splicing isoforms were present in NSCLC 
and even if translated seemed to be nonfunctional variants of ALK.
Key Words: Lung cancer, Non–small-cell lung cancer, Tyrosine 
kinase, Kinase inhibitor, Anaplastic lymphoma kinase, Crizotinib, 
Alternative splicing, Exon skipping, Exon 27, Exon 23.
(J Thorac Oncol. 2014;9: 248–253)
Anaplastic lymphoma kinase (ALK) rearrangements, either inversions or translocations, are present in approximately 
5% of all non–small-cell lung cancers (NSCLCs) at the time 
of diagnosis.1 The most frequent inversions event occur within 
the short arm of chromosome 2 and result in the fusion of 
the echinoderm microtubule-associated protein-like 4 (EML4) 
with ALK.2,3 The most common EML4-ALK fusion variants 
are E13;A20 and E20;A20.4
EML4-ALK variants are transforming tyrosine 
kinases that activate the phosphatidylinositol-3-kinase and 
 mitogen-activated protein kinase downstream pathways.5,6 
Tumors with EML4-ALK and other ALK rearrangements are 
oncogene addicted to ALK signaling and can be inhibited by 
ALK tyrosine kinase inhibitors (TKIs) in preclinical mod-
els.5,7,8 In the clinic, NSCLCs with ALK rearrangements are 
sensitive to the multitargeted ALK TKI crizotinib,9 and this 
drug received approval by the Food and Drug Administration 
in 2011 to be used in this NSCLC subtype.1 The reported 
response rates exceed 60% with a mean progression-free sur-
vival of more than 7–10 months before acquisition of resis-
tance to crizotinib monotherapy.10,11
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ALK kinase domain mutations and nonkinase domain 
splicing variants, which are present in a subset of neuroblas-
tomas,12 have not been reported in ALK TKI-naive NSCLCs. 
Our group reports herein the identification and characteriza-
tion of splicing isoforms of the kinase domain of ALK.
MATERIALS AND METHODS
Patient and Tumor Characteristics 
plus Statistical Methods
Two hundred sixty-eight Chinese patients from the Queen 
Mary Hospital (University of Hong Kong) and two patients 
from the Beth Israel Deaconess Medical Center with NSCLC 
were studied. Approval of this study was obtained from ongoing 
institutional review board-approved protocols at these institu-
tions. Clinical, pathologic, and molecular characteristics were 
obtained retrospectively from extraction of medical records.13 
Fisher’s exact test was performed to compare categorical vari-
ables and Student’s t test for continuous variables.
Sequencing of ALK
Total DNA and RNA were extracted using standard 
techniques. The expression of ALK kinase domain was initially 
screened by reverse transcriptase polymerase chain reaction 
(PCR) using forward (5′-GACCATCATGACCGACTACAA-3′) 
and reverse (5′-AGTGGACCATATTCTATCGGC-3′) primers 
flanking ALK exons 20 and 29, respectively. Cases showing 
splicing variations were confirmed by sequencing. Epidermal 
growth factor receptor (EGFR) mutations and KRAS mutations 
were analyzed as previously published.14,15 ALK rearrange-
ments were identified using ALK reverse transcriptase poly-
merase chain reaction primers or ALK fluorescence in vitro 
hybridization.9,16
Cell Culture
COS-7 cells were maintained in Dulbecco’s Modified 
Eagle’s Medium (Mediatech, Manassas, VA) supplemented 
with 10% fetal bovine serum. Ba/F3 cell lines were main-
tained in RPMI-1640 supplemented with 10% fetal bovine 
serum and 5% WEHI-conditioned medium as the source of 
interleukin-3 (IL-3).
Generation of Constructs/Vectors with 
EML4-ALK Variants and Reagents
The pcDNA3.1 EML4-ALK E13;A20 was a kind 
gift of Dr. Henry Koon (Case Western Reserve University, 
Cleveland, OH). The pcDNA3.1-Myc-His-Tag (Invitrogen, 
Carlsbad, CA) vector was used as the template for the intro-
duction of EML4-ALK E13;A20 (i.e., EML4-ALK vari-
ant 1) and mutated constructs for COS-7 experiments. The 
derived constructs EML4-ALK ALK p.L1196M, EML4-ALK 
ALK p.T1312fs*0, and ALK p.1312fs*0 were generated by 
 site-directed mutagenesis. Retroviral infection and selection 
of Ba/F3 cells for IL-3 independence were performed using 
previously described methods.17 Crizotinib was purchased 
from LC Laboratories (Woburn, MA), dissolved in dimethyl 
 sulfoxide, and stored at −80°C.
Western Blotting, Immunoprecipitation, 
and Antibodies
Cells were lysed and protein extracts obtained for analy-
sis.17 For immunoprecipitation, protein G agarose/sepharose 
beads were used for preclearing the cell lysates and captur-
ing the immunocomplex after incubation with the immuno-
precipitating antibody (Myc). Phospho-ALK (pTyr1096), 
ALK, phospho-Tyrosine (pTyr100), and Myc-Tag antibodies 
were purchased from Cell Signaling Technology (Beverly, 
MA). β-actin was purchased from Santa Cruz Biotechnology 
(Dallas, TX). Phospho-ALK was diluted 1:500 and all other 
primary antibodies were diluted 1:1000, whereas secondary 
antibodies were diluted 1:10000.
RESULTS
ALK Splicing Variants with Skipping 
of Exons 23 or 27 in NSCLC
We attempted to identify ALK kinase domain splicing 
abnormalities in NSCLC samples by analyzing cDNA derived 
from 270 cases of NSCLC (Table 1). Interestingly, the ALK 
kinase domain was solely expressed in 113 of 270 tumors 
(41.85%) (Fig. 1A). ALK kinase domain (i.e., exons 20–28) 
splicing variants were noted in 11.1% of cases (30 of 270). The 
major changes observed were either complete skipping of exon 
27 of ALK (ALKdel27) in 11 cases or complete skipping of exon 
23 of ALK (ALKdel23) in 19 cases (Fig. 1B and C, respectively). 
Both splicing isoforms have a nucleotide sequence that leads 
to early stop codons (Fig. 1D): ALKdel27 to the protein ALK 
p.T1312fs*0 and ALKdel23 to ALK p.I1171fs*42.
The clinical, pathological, and molecular characteristics 
of NSCLCs with or without splicing abnormalities of ALK were 
similar (Table 1). ALK splicing variants were observed in cases 
with or without ALK rearrangements, KRAS mutations, and 
EGFR mutations (Table 1). Of the four cases with ALK rear-
rangements and ALK splicing variants, one had EML4-ALK with 
ALKdel27 and three had EML4-ALK with ALKdel23 (Table 1). 
Only the EML4-ALKdel27 case received crizotinib. Of the cases 
with EML4-ALKdel23, two remain free of disease after curative 
surgical resection and one had recurrence 29 months after sur-
gical resection and died before crizotinib therapy.
EML4-ALK Positive NSCLC with ALKdel27
The EML4-ALK rearranged NSCLC that harbored 
ALKdel27 had crizotinib-resistant malignant lymphatic tissue 
analyzed in our group’s attempt to sequence the ALK kinase 
domain of crizotinib-naive and crizotinib-resistant NSCLCs. 
The patient had attained significant symptomatic response 
and minor tumor regression of his intrathoracic disease best 
classified as stable disease for 8 months before develop-
ment of  crizotinib-resistant lesions.18 cDNA derived from 
 crizotinib-resistant EML4-ALK positive left axillary node tis-
sue was sequenced to encompass exons 20 to 28 of ALK. We 
identified an overlapping sequence amid the wild-type ALK 
kinase domain of this EML4-ALK fusion, which corresponded 
to complete skipping of exon 27 of ALK (Fig. 2A). cDNA 
isolated from nonmalignant lymphoid tissue from the same 
patient only contained ALK and not EML4-ALK, and ALK 
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T1312fs*0 was not present (data not shown). Interestingly, 
the  crizotinib-naive tumor from the patient also disclosed 
 EML4-ALK with ALK T1312fs*0. Sequence of the exon–
intron junction of exons 26 to 27 and 27 to 28 using DNA 
isolated from the  crizotinib-resistant sample did not yield 
abnormal sequences.
EML4-ALKdel27 Generates the Truncated 
EML4-ALK T1312fs*0 Protein with 
Inability to Autophosphorylate ALK
Because both ALKdel27 and ALKdel23 would poten-
tially lead to truncated proteins lacking the full kinase domain 
of ALK (Fig. 1D), we wanted to understand the biological 
properties of one of these splicing variants, if translated into 
protein. We decided to study the skipping of exon 27 of ALK 
(T1312fs*0) in the context of EML4-ALK and to this end gen-
erated EML4-ALK E13;A20 (EML4-ALK) constructs with or 
without ALK T1312fs*0 and in addition EML4-ALK with ALK 
L1196M. The latter is known to represent a  crizotinib-resistant 
gatekeeper mutation.19
The EML4-ALK and EML4-ALK L1196M constructs 
expressed proteins of their expected size of close to 117 kDa 
(Fig. 2B). Nevertheless, the EML4-ALK T1312fs*0 protein 
was identified at a size of ~80 kDa (Fig. 2B). The latter results 
indicated that EML4-ALKdel27 could generate a truncated 
EML4-ALK protein.
We then decided to study the functional proper-
ties of EML4-ALK T1312fs*0. Using an antibody spe-
cific for a phosphorylation site within amino acid 1096 
(tyrosine 1096) of ALK (which is still present within ALK 
T1312fs*0), we were only able to detect autophosphoryla-
tion of ALK in EML4-ALK and EML4-ALK L1196M, 
whereas  EML4-ALK T1312fs*0 did not have a detectable 
signal (Fig. 2C). We also performed an immunoprecipita-
tion experiment to detect autophosphorylation of tyrosine 
residues within ALK or other proteins bound to EML4-ALK 
using a phosphotyrosine antibody. EML4-ALK T1312fs*0 
was unable to generate a measurable signal (Fig. 2C). These 
results confirmed that EML4-ALK T1312fs*0 was unable to 
phosphorylate tyrosine sites and was a nonfunctional kinase 
when expressed alone. We attempted to transform a cell line 
system with ALK T1312fs*0, but it was ineffective in mak-
ing Ba/F3 cells IL-3 independent (data not shown). Because 
ALK p.I1171fs*42 lacks all the amino acid sites of ALK 
T1312fs*0 in addition to other areas of the ALK kinase, we 
can foretell it will similarly be unable to transform cell line 
systems. EML4-ALK and EML4-ALK L1196M can make 
Ba/F3 cells IL-3 independent.20,21
EML4-ALK T1312fs*0 and Response 
to the ALK TKI Crizotinib
Although we demonstrated that EML4-ALK 
T1312fs*0 was potentially nonfunctional as a “driver” onco-
gene, we also tested the possibility that this truncated protein 
could affect the exquisite sensitivity of EML4-ALK toward 
the ALK TKI crizotinib. When EML4-ALK was transfected 
alone, we were able to observe that the inhibition of phos-
phorylation of ALK by crizotinib occurred at doses of 0.1 
μM (Fig. 2D). When we cotransfected equal amounts of 
 EML4-ALK and EML4-ALK T1312fs*0, we observed that 
the inhibition of phosphorylation of ALK within  EML4-ALK 
was unaffected and crizotinib continued to inhibit ALK at 
doses of 0.1 μM (Fig. 2D). When EML4-ALK and EML4-
ALK L1196M were cotransfected in equal amounts, then a 
shift in the pattern of inhibition of phosphorylation of ALK 
was noted (Fig. 2D); confirming that EML4-ALK L1196M 
is a  crizotinib-resistant mutation. Taken together, these 
results led us to speculate that EML4-T1312fs*0 was not 
involved in the pattern of either sensitivity or resistance of 
 EML4-ALK to crizotinib.
TABLE 1.  Baseline Patient, Tumor, and Molecular 
Characteristics of Non–Small-Cell Lung Cancers with or with-
out ALK Kinase Domain Splicing Variants
Total (n = 270)
ALK Kinase 
Domain Splicing 
Variant Expression 
(n = 30)
Lack of ALK Kinase 
Domain Splicing  
Variant Expression  
(n = 240) p
Age median (range) 61 (29–81) 64 (33–79) 0.110
Women, n (%) 13 (43.3) 123 (51.2) 0.444
Race, n (%)
  Asian 29 (96.7) 239 (99.6)
0.210
  White 1 (3.3) 1 (0.4)
Smoking status, n (%)
  Current smoker 12 (40.0) 77 (32.1)
0.660  Former smoker 4 (13.3) 33 (13.8)
  Never smoker 14 (46.7) 130 (54.1)
Stage, n (%)
  I 16 (53.3) 138 (57.5)
0.033
  II 2 (6.7) 45 (18.8)
  III 9 (30.0) 52 (21.7)
  IV 3 (10.0) 5 (2.1)
Histology, n (%)
  Adenocarcinoma 24 (80.0) 189 (78.8)
0.925
  Squamous cell 
carcinoma
4 (13.3) 30 (12.5)
  Other (NOS) 2 (6.7) 21 (8.7)
EGFR mutation, n (%)
  Positive/mutated 9 (30) 116 (48.3)
0.079
  Negative/wild type 21 (70) 124 (51.7)
KRAS mutation, n (%)
  Positive/mutated 3 (10) 19 (7.9)
0.721
  Negative/wild type 27 (90) 221 (92.1)
ALK rearrangement, n (%)
  Positive 4 (13.3) 15 (6.2)
0.244
  Negative 26 (86.6) 225 (93.8)
ALK splicing variant, n (%)
  Exon 23 skipping 19 (63.3) 0 (0)
NA  Exon 27 skipping 11 (36.7) 0 (0)
ALK, anaplastic lymphoma kinase; NOS, not otherwise specified; EGFR, epidermal 
growth factor receptor; KRAS, v-ki-ras2 Kirsten rat sarcoma viral oncogene homolog; 
NA, not applicable.
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DISCUSSION
We identified ALK splicing variants, involving the com-
plete skipping of exons 23 and 27 of ALK, in samples with 
NSCLC. To the best of our knowledge, these results represent 
the first attempt to understand the biological and clinical sig-
nificance of ALK kinase domain splicing variants in NSCLC. 
In our cohort of 270 patients, more than 10% of NSCLCs 
harbored either ALKdel23 (~7% of cases) or ALKdel27 (~4% 
of cases). Nevertheless, it is noteworthy that most tumors 
(58.15% [157 of 270]) did not even demonstrate expression of 
the ALK kinase domain. This observation is supported by the 
known low to absent expression of ALK in most lung tumors 
that do not harbor ALK rearrangements.11,22,23 More interest-
ingly, ALK splicing variants were noted to coexist not only 
with ALK rearrangements in some samples but also with other 
oncogenic driver mutations (in specific EGFR and KRAS 
mutations). The latter may be indicative that ALK kinase 
domain splicing variants are “passenger” events in NSCLCs.
The other known tumor type with oncogenic ALK abnor-
malities that has been shown to display ALK splicing variants 
is neuroblastoma. In this tumor type, characterized by muta-
tions within the tyrosine kinase of ALK in a subset of samples, 
truncated ALK proteins with complete skipping of exons 
2 to 3 (ALKdel2-3) and exons 4 to 11 (ALKdel4-11) of ALK 
have been described and characterized.24,25 Different than the 
 EML4-ALKdel27-derived protein EML4-ALK T1312fs*0 
described herein by us, these truncated extracellular domain 
proteins led to increased constitutive kinase activity of ALK and 
transformation potential (i.e., ALKdel2-3 and ALKdel4-11 were 
putative driver events). It is possible to speculate that the oppo-
site nature of these proteins is based on the fact that ALKdel2-3 
and ALKdel4-11 retain the sequence of the active kinase domain 
of ALK, whereas ALKdel27 leads to a stop codon that occurs 
within the tyrosine kinase domain. The lack of a functional 
complete tyrosine kinase domain may explain the nonfunc-
tional nature of the EML4-ALK T1312fs*0 truncated protein. 
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FIGURE 1.  Screening for ALK 
kinase domain splicing variants in 
NSCLC. A, Reverse transcriptase PCR 
using primers that flank exons 20 
to 29 of ALK (encompass the kinase 
domain). Cases with or without ALK 
kinase domain expression and those 
expressing ALK slicing variants. B, 
Sequence chromatogram of a tumor 
specimen with complete skip-
ping of exon 27 of ALK (ALKdel27). 
Representative sequences from cDNA 
isolated from case no. 72 highlight-
ing the ALK exons 26 to 27 and ALK 
exons 26 to 28 coexisting sequences. 
C, Sequence chromatogram of a 
tumor specimen with complete skip-
ping of exon 23 of ALK (ALKdel23). 
Representative sequences from cDNA 
isolated from case no. 20 highlight-
ing the ALK exons 22 to 23 and ALK 
exons 22 to 24 coexisting sequences. 
Reference ALK gene sequence 
(NM_004304.3; homo sapiens ALK 
mRNA). D, Proposed amino acid 
sequence of WT ALK, ALKdel27 
and ALKdel23. The latter trun-
cated proteins generate early stop 
codons. *, A STOP codon sequence; 
ALK, anaplastic lymphoma kinase; 
NSCLC, non–small-cell lung cancer; 
PCR, polymerase chain reaction; 
WT, wild type; EML4, echinoderm 
 microtubule-associated protein-like 4.
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FIGURE 2.  Evaluation of EML4-ALK T1312fs*0 in preclinical models. A, Sequence chromatogram of an EML4-ALK positive 
tumor specimen. Representative sequences from cDNA isolated from the aforementioned lymph node. Nucleotide areas cor-
responding to ALK exons 26, 27, and 28 are highlighted. Reference ALK gene sequence (NM_004304.3; homo sapiens ALK 
mRNA); the expected nucleotide and amino acid sequences for the wild-type ALK exons 26 to 27 junction and for the splicing 
variant with ALK exons 26 to 28 junction are shown. The latter generates the early stop codon sequence p.T1312fs*0  (n.TGG-
>TGA). B, Western blot analysis of protein extracts from COS-7 cells transfected with EML4-ALK constructs and empty vector. 
EML4-ALK E13;A20 constructs with a 3′ Myc-His-Tag were cloned into pcDNA3.1. COS-7 cells were transfected with 1 μg of 
DNA and protein extracts were collected 24 hours later. The radiograph shows the expression of phosphorylated ALK (p-ALK 
Tyr1096) and EML4-ALK detected by using a Myc-Tag antibody. EML4-ALK T1312fs*0 results in a 80 kDa protein, different 
from the expected size—117 kDa—of EML4-ALK WT and EML4-ALK containing the L1196M crizotinib-resistant mutation. C, 
Western blot analysis of protein extracts from COS-7 cells transfected with EML4-ALK-Myc-His-Tag constructs or empty vector 
and immunoprecipitated with Myc-Tag antibody. The upper figure shows the expression of p-TYR and the lower figure shows 
the expression of EML4-ALK detected by using a Myc-Tag antibody. EML4-ALK T1312fs*0 results in an 80 kDa protein that is 
not phosphorylated. D, Western blot analysis of protein extracts from COS-7 cells cotransfected with different DNA amounts of 
EML4-ALK constructs and empty vector and treated with crizotinib or vehicle (DMSO). The left panel with E13;A20 EML4-ALK 
(0.4 μg) + empty vector (0.6 μg); the middle with EML4-ALK (0.4 μg) + empty vector (0.2 μg) + EML4-ALK T1312fs*0 (0.4 
μg) in which EML4-ALK T1312fs*0 does not result in resistance to crizotinib as verified by ALK phosphorylation inhibition using 
Tyr1096 phospho-ALK antibody; the right with EML4-ALK (0.4 μg) + empty vector (0.2 μg) + EML4-ALK L1196M (0.4 μg) in 
which the cotransfection of EML4-ALK L1196M is shown in the right panel and discloses resistance to inhibition of  phospho-ALK 
by crizotinib. Blots were cropped to highlight the referenced molecular weight. EML4, echinoderm microtubule-associated 
protein-like 4; ALK, anaplastic lymphoma kinase; p-TYR, phosphotyrosine.
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Therefore, ALKdel27 seems to be a silent variant that indeed 
is a passenger alternative splicing form of ALK. ALKdel23 
(ALK I1171fs*42), due to its even more significant lack of resi-
dues within the ALK kinase domain, is also expected to be a 
truncated and nonfunctional variant if translated.
Interestingly, the currently approved and/or used meth-
ods of detection of ALK rearrangements in clinical practice 
are unable to obtain sequence reads of the introns and exons 
spanning the kinase domain of ALK.1,9,16 Even robust targeted 
next-generation sequencing techniques26 using tumor-derived 
genomic DNA as a template would not be able to identify a 
splicing mutation or exon skipping variant within ALK. These 
limitations highlight the possible lack of reporting of ALK 
splicing variants in NSCLC.
The identification of mechanisms of resistance to crizo-
tinib and other ALK TKIs in ALK rearranged NSCLC is of 
utmost importance, and to date, only ALK kinase mutations 
and/or bypass tracks due to activation of other oncogenes 
(such as EGFR) have been described.11,17,27–29 ALK kinase 
mutations—which are present in only approximately one 
third of crizotinib-resistant samples—have been characterized 
in vitro as crizotinib-resistant mutations using EML4-ALK 
driven models.29 We were able to confirm that EML4-ALK 
with the gatekeeper ALK-L1196M indeed is resistant to crizo-
tinib. Our preclinical characterization of EML4-ALKdel27 
and the resulting truncated EML4-ALK T1312fs*0 mutated 
protein add to these prior results by annotating a nonfunc-
tional and nonresistant inducing variant of EML4-ALK. The 
translation of these results into the clinic would inform future 
investigators not to alter their ALK TKI treatment strategies 
in the presence of ALKdel27. The patient in which we identi-
fied EML4-ALKdel27 had this variant present together with 
 wild-type EML4-ALK in his crizotinib-naive and resistant 
samples. His marked response to crizotinib18 does not seem to 
have been affected by EML4-ALKdel27.
In summary, our group report that splicing iso-
forms of the kinase domain of ALK (either ALKdel23 or 
ALKdel27) were identified in 11.1% of NSCLCs, and these 
ALK kinase splicing variants were nonfunctional genomic 
events in NSCLC.
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